GILEAD SCIENCES, INC. is 93.5x more valuable than RECURSION PHARMACEUTICALS, INC. by market capitalization ($150.83 B vs $1.61 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | RXRX | GILD |
|---|---|---|
| Market cap | $1.61 B | $150.83 B |
| US-listed rank | #2258 | #99 |
| Revenue (latest FY) | $74.68M | $29.44B |
| Net income (latest FY) | -$644.76M | $8.51B |
| Net margin | -863.4% | 28.9% |
| P/E (trailing FY) | - | 17.7 |
| SEC filings | 908 | 981 |
GILEAD SCIENCES, INC. is 93.5x more valuable than RECURSION PHARMACEUTICALS, INC. by market capitalization ($150.83 B vs $1.61 B).
In their latest fiscal years, RECURSION PHARMACEUTICALS, INC. reported $74.68M in revenue while GILEAD SCIENCES, INC. reported $29.44B.
Full pages: RECURSION PHARMACEUTICALS, INC. and GILEAD SCIENCES, INC., or browse the full rankings.